Targeted inhibition of IL-18 attenuates irinotecan-induced intestinal mucositis in mice

British Journal of Pharmacology

Volumn 171, Issue 9, 2014, Pages 2335-2350

  Lima Junior R C P ^a   Freitas, H C ^b   Wong, D V T ^a   Wanderley, C W S ^a   Nunes, L G ^a   Leite, L L ^a   Miranda, S P ^a   Souza, M H L P ^a   Brito, G A C ^a   Magalhaes P J C ^a   Teixeira, M M ^c   Cunha, F Q ^d   Ribeiro, Ronaldo Albuquerque ^a,e  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e Instituto do Cancer do Ceara   (Brazil)

Author keywords

cancer chemotherapy toxicity; gut; IL 18; IL 18 binding protein; inflammation; irinotecan; mucositis

Indexed keywords

GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME; IRINOTECAN; MYELOPEROXIDASE; CAMPTOTHECIN; INTERLEUKIN-18 BINDING PROTEIN; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIARRHEA; DISEASE SEVERITY; ENTERITIS; ENZYME ACTIVITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTESTINAL MUCOSITIS; INTESTINE CONTRACTION; INTESTINE INJURY; INTESTINE MUSCLE; KNOCKOUT MOUSE; MACROPHAGE; MOUSE; MUCOSA INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; INTESTINE MUCOSA; METABOLISM; MUCOSITIS; ORGAN CULTURE TECHNIQUE; PROCEDURES; TOXICITY;

ANIMALS; CAMPTOTHECIN; DRUG DELIVERY SYSTEMS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-18; INTESTINAL MUCOSA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MUCOSITIS; ORGAN CULTURE TECHNIQUES;

EID: 84898618327     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12584     Document Type: Article

References (40)

1. Alvarez B, Radi R, (2003). Peroxynitrite reactivity with amino acids and proteins. Amino Acids 25: 295-311. (Pubitemid 38041267)
2. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. (2000). Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405: 458-462. (Pubitemid 30367422)
3. Bradley PP, Christensen RD, Rothstein G, (1982). Cellular and extracellular mieloperoxidase in pyogenic inflammation. Blood 60: 618-622. (Pubitemid 12027137)
4. Bredt DS, Snyder SH, (1989). Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci U S A 86: 9030-9033. (Pubitemid 20010361)
5. Chikano S, Sawada K, Shimoyama T, Kashiwamura SI, Sugihara A, Sekikawa K, et al. (2000). IL-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-gamma dependent manner. Gut 47: 779-786.
6. Dinarello CA, (2001). Novel targets for interleukin 18 binding protein. Ann Rheum Dis 60 (Suppl. 3): iii18-iii24. (Pubitemid 32980438)
7. Dinarello CA, Novick D, Kim S, Kaplanski G, (2013). Interleukin-18 and IL-18 binding protein. Front Immunol 4: 1-10.
8. Gibson RJ, Keefe DM, (2006). Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer 14: 890-900.
9. Gibson RJ, Keefe DM, Lalla RV, Bateman E, Blijlevens N, Fijlstra M, et al. (2013). Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 21: 313-326.
10. Hanahan D, Weinberg RA, (2011). Hallmarks of cancer: the next generation. Cell 144: 646-674.
11. Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A, (2008) the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess 12: iii-ix, xi-162.
12. Hsu SM, Raine L, (1981). Protein A, avidin, and biotin in immunohistochemistry. J Histochem Cytochem 29: 1349-1353. (Pubitemid 12231851)
13. Hyatt JL, Tsurkan L, Morton CL, Yoon KJ, Harel M, Brumshtein B, et al. (2005). Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11. Chem Biol Interact 157-158: 247-252. (Pubitemid 41757658)
14. Ikuno N, Soda H, Watanabe M, Oka M, (1995). Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and caecum. J Natl Cancer Inst 87: 1876-1883.
15. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, et al. (2007). Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109: 820-831. (Pubitemid 46335677)
16. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
17. Krishna SG, Zhao W, Grazziutti ML, Sanathkumar N, Barlogie B, Anaissie EJ, (2011). Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients: clinical and research implications. Cancer 117: 648-655.
18. Kurita A, Kado S, Kaneda N, Onoue M, Hashimoto S, Yokokura T, (2000). Modified irinotecanhydrochloloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats. Cancer Chemother Pharmacol 46: 211-220.
19. Leach ST, Messina I, Lemberg DA, Novick D, Rubenstein M, Day AS, (2008). Local and systemic interleukin-18 and interleukin-18-binding protein in children with inflammatory bowel disease. Inflamm Bowel Dis 14: 68-74. (Pubitemid 351196871)
20. Leitão RF, Ribeiro RA, Bellaguarda EA, Macedo FD, Silva LR, Oriá RB, et al. (2007). Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster. Cancer Chemother Pharmacol 59: 603-612. (Pubitemid 46295124)
21. Leitão RF, Brito GA, Oriá RB, Braga-Neto MB, Bellaguarda EA, Silva JV, et al. (2011). Role of inducible nitric oxide synthase pathway on methotrexate-induced intestinal mucositis in rodents. BMC Gastroenterol 11: 90.
22. Lima-Júnior RC, Figueiredo AA, Freitas HC, Melo ML, Wong DV, Leite CA, et al. (2012). Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation. Cancer Chemother Pharmacol 69: 931-942.
23. Livak KJ, Schmittgen TD, (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
24. Matsunaga H, Hokari R, Ueda T, Kurihara C, Hozumi H, Higashiyama M, et al. (2011). Physiological stress exacerbates murine colitis by enhancing proinflammatory cytokine expression that is dependent on IL-18. Am J Physiol Gastrointest Liver Physiol 301: G555-G564.
25. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
26. Melo ML, Brito GA, Soares RC, Carvalho SB, Silva JV, Soares PM, et al. (2008). Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide. Cancer Chemother Pharmacol 61: 775-784. (Pubitemid 351302033)
27. Nakao T, Kurita N, Komatsu M, Yoshikawa K, Iwata T, Utusnomiya T, et al. (2012). Irinotecan injures tight junction and causes bacterial translocation in rat. J Surg Res 173: 341-347.
28. Pavlov VA, Ochani M, Yang LH, Gallowitsch-Puerta M, Ochani K, Lin X, et al. (2007). Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit Care Med 35: 1139-1144. (Pubitemid 46598966)
29. Peterson DE, Bensadoun RJ, Roila F, (2011). Management of oral and gastrointestinal mucositis: ESMO clinical practice guidelines. Ann Oncol 22 (Suppl. 6): vi78-vi84.
30. Ribeiro RA, Flores CA, Cunha FQ, Ferreira SH, (1991). IL-8 causes in vivo neutrophil migration by a cell-dependent mechanism. Immunology 73: 472-477.
31. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, et al. (2004). Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100 (9 Suppl.): 2026-2046. (Pubitemid 38525884)
32. Sahoo M, Ceballos-Olvera I, del Barrio L, Re F, (2011). Role of the inflammasome, IL-1β, and IL-18 in bacterial infections. ScientificWorldJournal 11: 2037-2050.
33. Soares PM, Mota JM, Souza EP, Justino PF, Franco AX, Cunha FQ, et al. (2013). Inflammatory intestinal damage induced by 5-fluorouracil requires IL-4. Cytokine 61: 46-49.
34. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, et al. (2001). Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19: 2201-2205. (Pubitemid 32372323)
35. van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LA, (2011). Inflammasome activation and IL-1β and IL-18 processing during infection. Trends Immunol 32: 110-116.
36. Verri WA Jr, Cunha TM, Ferreira SH, Wei X, Leung BP, Fraser A, et al. (2007). IL-15 mediates antigen-induced neutrophil migration by triggering IL-18 production. Eur J Immunol 37: 3373-3380.
37. Volin MV, Koch AE, (2011). Interleukin-18: a mediator of inflammation and angiogenesis in rheumatoid arthritis. J Interferon Cytokine Res 31: 745-751.
38. Wenzl HH, (2012). Diarrhea in chronic inflammatory bowel diseases. Gastroenterol Clin North Am 41: 651-675.
39. Wyburn KR, Chadban SJ, Kwan T, Alexander SI, Wu H, (2013). Interleukin-18 binding protein therapy is protective in adriamycin nephropathy. Am J Physiol Renal Physiol 304: F68-F76.
40. Xynos ID, Karadima ML, Voutsas IF, Amptoulach S, Skopelitis E, Kosmas C, et al. (2013). Chemotherapy ± cetuximab modulates peripheral immune responses in metastatic colorectal cancer. Oncology 84: 273-283.